0.05). Mean serum insulin-like growth factor-1 levels were 219 ng/ml for the case group and 133 ng/ml for the control group, which was significant (P=0.0009). We did not observe any correlation between age and insulin-like growth factor-1 in the case group (P=0.83, r= -0.47), however there was a significant correlation in the control group (P=0.007, r=0.549). Although correlation between prostate volume and serum insulin-like growth factor-1 levels was not statistically significant in the case group (P=0.38, r=0.213), there was a positive correlation observed in the control group (p <0.008, r=0.537). Conclusion: Our findings suggest that insulin-like growth factor-1 may have an etiologic role in prostate cancer. This interpretation is strengthened by the significant difference observed between serum insulin-like growth factor-1 levels in benign prostatic hyperplasia and prostate cancer patients. These results also offer additional opportunities for evaluating patients who have abnormal digital rectal exams or prostate specific antigen levels, yet their biopsies are normal. Under these circumstances, measurement of serum insulin-like growth factor-1 may assist with the decision for a second biopsy.]]>
p. 95−99
2008-6687
Vol.3/No.4
p. 101−108
2008-6687
Vol.3/No.4
p. 109−117
2008-6687
Vol.3/No.4
p. 119−129
2008-6687
Vol.3/No.4
24 months (P=0.0095), disease stage (P=0.0014), and blastimal subtype (P=0.006) were associated with significant increases in relapse rate.Conclusion: Preoperative chemotherapy resulted in a final stage redistribution that placed the majority of patients in the early stages of the disease. Age at diagnosis, disease stage, and histological subtype significantly affected survival and relapse rates.]]>
p. 131−140
2008-6687
Vol.3/No.4